Literature DB >> 12502983

Systemic inflammation leads to resistance to atracurium without increasing membrane expression of acetylcholine receptors.

Heidrun Fink1, Peter Luppa, Barbara Mayer, Hilkea Rosenbrock, Jochen Metzger, J A Jeevendra Martyn, Manfred Blobner.   

Abstract

BACKGROUND: Systemic inflammation may be associated with resistance to nondepolarizing neuromuscular blocking drugs, the mechanisms of which are, however, uncharacterized. The authors therefore investigated the pharmacodynamics of atracurium and its relation to the expression of nicotinic acetylcholine receptors and alpha1 -acid glycoprotein in a rat model of systemic inflammation.
METHODS: To induce a systemic inflammation, male CD rats received 56 mg/kg corynebacterium parvum intravenously. On days 2, 4, 6, 8, 10, 12, 14, or 16 after infection, neuromuscular transmission was measured. The individual effective dose of atracurium was determined, followed by an atracurium infusion at a rate to establish a steady state neuromuscular block of 50%. Total and unbound plasma concentrations of atracurium for 50% paralysis were measured using high-performance liquid chromatography. Acetylcholine receptors were quantitated using 125I-alpha-bungarotoxin. alpha1 -Acid glycoprotein concentrations in the serum were measured using a competitive chemiluminescence immunoassay.
RESULTS: The effective dose of atracurium was increased on days 4, 6, and 8. Total atracurium plasma concentrations at 50% neuromuscular paralysis were increased on days 4, 6, 8, and 10, with a peak at day 8 (8.0 +/- 1.3 micro g/ml) compared with control rats (4.23 +/- 0.82 micro g/ml). The alpha1 -acid glycoprotein concentrations were increased between days 2 and 10, with a peak on day 4 (6.52 +/- 1.45 mg/ml), and recovered to control values (0.61 +/- 0.33 mg/ml) on day 12. Unbound plasma concentrations of atracurium to achieve 50% depression, as well as the expression of acetylcholine receptors, did not differ between groups.
CONCLUSION: Resistance to atracurium during corynebacterium parvum-induced systemic inflammation is due to increased drug binding to alpha1 -acid glycoprotein and is unrelated to changes in acetylcholine receptor expression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12502983     DOI: 10.1097/00000542-200301000-00016

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  8 in total

Review 1.  Antiepileptic-induced resistance to neuromuscular blockers: mechanisms and clinical significance.

Authors:  Sulpicio G Soriano; J A Jeevendra Martyn
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

2.  A single injection of botulinum toxin decreases the margin of safety of neurotransmission at local and distant sites.

Authors:  Christiane G Frick; Heidrun Fink; Manfred Blobner; Jeevendra Martyn
Journal:  Anesth Analg       Date:  2011-10-14       Impact factor: 5.108

3.  Interpretation of drug concentrations in an alternative matrix: the case of meprobamate in bile.

Authors:  L Fanton; F Bevalot; M P Gustin; C Z Paultre; C Le Meur; D Malicier
Journal:  Int J Legal Med       Date:  2008-06-26       Impact factor: 2.686

4.  The pharmacokinetics and pharmacodynamics of cisatracurium in critically ill patients with severe sepsis.

Authors:  Xin Liu; Peter S Kruger; Michael Weiss; Michael S Roberts
Journal:  Br J Clin Pharmacol       Date:  2012-05       Impact factor: 4.335

5.  Chronic Escherichia coli infection induces muscle wasting without changing acetylcholine receptor numbers.

Authors:  Christiane G Frick; Heidrun Fink; Maria L Gordan; Barbara Eckel; J A Jeevendra Martyn; Manfred Blobner
Journal:  Intensive Care Med       Date:  2007-10-20       Impact factor: 17.440

6.  GTS-21 attenuates loss of body mass, muscle mass, and function in rats having systemic inflammation with and without disuse atrophy.

Authors:  Stefan J Schaller; Michio Nagashima; Martin Schönfelder; Tomoki Sasakawa; Fabian Schulz; Mohammed A S Khan; William R Kem; Gerhard Schneider; Jürgen Schlegel; Heidrun Lewald; Manfred Blobner; J A Jeevendra Martyn
Journal:  Pflugers Arch       Date:  2018-07-13       Impact factor: 3.657

7.  Complete resistance after maximal dose of rocuronium.

Authors:  Annalisa Capuano; Maria Giuseppa Sullo; Concetta Rafaniello; Liberata Sportiello; Pierfrancesco Fusco; Macella De Vizia; Fausto Ferraro
Journal:  J Pharmacol Pharmacother       Date:  2015 Jul-Sep

8.  Orosomucoid 1 promotes epirubicin resistance in breast cancer by upregulating the expression of matrix metalloproteinases 2 and 9.

Authors:  Luo Qiong; Jun Yin
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.